Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050097 | 1.00 | MAPT (0.37) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23064279 | 1.00 | MAPT (0.37) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23064280 | 1.00 | MAPT (0.37) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23064379 | 1.00 | MAPT (0.37) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23701853 | 0.85 | SCD (0.43) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23733260 | 0.85 | TRPV1 (0.39) | MAPTTRPV1SCDSCD5RORC | |
| SCHEMBL23283038 | 0.77 | TRPV1 (0.39) | MAPTTRPV1SCDSCD5PDK4 | |
| SCHEMBL25844259 | 0.70 | TRPA1 (0.48) | TRPV1HSD11B1 | |
| SCHEMBL23064245 | 0.67 | ALDH1A1 (0.48) | MAPTSCDSCD5PDK4 | |
| SCHEMBL3325476 | 0.67 | MAPT (0.50) | MAPTTRPV1PDK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4487848-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-01-08 | — | — | EP | disclosed |
| EP-4461296-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | Osaka University (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118678955-A | Pharmaceutical composition for preventing and/or treating heart failure | 国立大学法人大阪大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | KYOTO UNIVERSITY (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | ATG7, BECN1, SQSTM1 | MAPT 3823/4885TRPV1 1502/4885SCD 3494/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | MAPT 4736/4885TRPV1 2373/4885SCD 3675/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | MAPT 4874/4885TRPV1 2978/4885SCD 4229/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | MAPT 4805/4885TRPV1 1496/4885SCD 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.